SCHEMBL7050641

SCHEMBL7050641

CCOC(=O)c1ccc(N2CCCCC2Nc2ncccn2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
NR1H2 P55055 3/20 0.40
CDK4 P11802 3/20 0.39
CCND1 P24385 3/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NOS2 P35228 1/20 0.37
ELANE P08246 1/20 0.37
JMJD6 Q6NYC1 1/20 0.37
MAPK1 P28482 1/20 0.36
NR1H3 Q13133 1/20 0.36
RAB9A P51151 2/20 0.36
FGFR1 P11362 1/20 0.36
CCNA2 P20248 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR4 P22455 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7466043 0.90 OPRK1 (0.43) OPRK1L3MBTL1POLBMAPTCDK4
SCHEMBL7470661 0.89 OPRK1 (0.42) OPRK1MAPTCDK4CCND1NOS2
SCHEMBL7466384 0.88 OPRK1 (0.40) OPRK1POLBMAPTNR1H2CDK4
SCHEMBL7051584 0.85 KDM4E (0.37) MAPTCDK4CCND1MEN1KMT2A
SCHEMBL7054704 0.84 ALDH1A1 (0.45) OPRK1POLBMAPTMAPK1RAB9A
SCHEMBL382148 0.81 MAPT (0.46) MAPTMEN1KMT2ANOS2MAPK1
SCHEMBL7050644 0.80 OPRK1 (0.49) OPRK1L3MBTL1TDP1POLBMAPT
SCHEMBL7052909 0.80 RAB9A (0.43) L3MBTL1TDP1POLBMAPTMEN1
SCHEMBL7463190 0.75 GCK (0.40) MAPTCDK4CCND1MEN1KMT2A
SCHEMBL7474418 0.75 NPC1 (0.52) MAPTNOS2MAPK1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist MEIJI SEIKA KAISHA, LTD. (JP) 2003-02-27 US disclosed
EP-1250935-A1 REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST MEIJI SEIKA KAISHA LTD. (JP) 2002-10-23 EP disclosed
EP-1227083-A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS MEIJI SEIKA KAISHA LTD. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040531-A1 Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist ITGB3, ITGAV, ITGB1 OPRK1 639/4885L3MBTL1 1833/4885TDP1 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.